Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis.
Saved in:
| Title: | Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis. |
|---|---|
| Authors: | Shahzad M; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; Moffitt Cancer Center, University of South Florida, Tampa, FL., Hussain A; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS., Tariq E; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS., Anwar I; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS., Faisal MS; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS., Syed L; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS., Karam A; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS., Chaudhary SG; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS., Ahmed N; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS., Bansal R; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS., Khurana S; Division of Hematology/Oncology, University of Arizona College of Medicine, Tucson, AZ., Singh AK; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS., Byrd KP; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS., Hematti P; Division of Hematology/Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI., Abhyankar SH; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS., McGuirk JP; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS., Mushtaq MU; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS. Electronic address: mmushtaq@kumc.edu. |
| Source: | Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2023 Mar; Vol. 23 (3), pp. 178-187. Date of Electronic Publication: 2023 Jan 12. |
| Publication Type: | Meta-Analysis; Systematic Review; Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 36682989 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Shahzad+M%22">Shahzad M</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS; Moffitt Cancer Center, University of South Florida, Tampa, FL.<br /><searchLink fieldCode="AU" term="%22Hussain+A%22">Hussain A</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.<br /><searchLink fieldCode="AU" term="%22Tariq+E%22">Tariq E</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.<br /><searchLink fieldCode="AU" term="%22Anwar+I%22">Anwar I</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.<br /><searchLink fieldCode="AU" term="%22Faisal+MS%22">Faisal MS</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.<br /><searchLink fieldCode="AU" term="%22Syed+L%22">Syed L</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.<br /><searchLink fieldCode="AU" term="%22Karam+A%22">Karam A</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.<br /><searchLink fieldCode="AU" term="%22Chaudhary+SG%22">Chaudhary SG</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.<br /><searchLink fieldCode="AU" term="%22Ahmed+N%22">Ahmed N</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.<br /><searchLink fieldCode="AU" term="%22Bansal+R%22">Bansal R</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.<br /><searchLink fieldCode="AU" term="%22Khurana+S%22">Khurana S</searchLink>; Division of Hematology/Oncology, University of Arizona College of Medicine, Tucson, AZ.<br /><searchLink fieldCode="AU" term="%22Singh+AK%22">Singh AK</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.<br /><searchLink fieldCode="AU" term="%22Byrd+KP%22">Byrd KP</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.<br /><searchLink fieldCode="AU" term="%22Hematti+P%22">Hematti P</searchLink>; Division of Hematology/Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.<br /><searchLink fieldCode="AU" term="%22Abhyankar+SH%22">Abhyankar SH</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.<br /><searchLink fieldCode="AU" term="%22McGuirk+JP%22">McGuirk JP</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS.<br /><searchLink fieldCode="AU" term="%22Mushtaq+MU%22">Mushtaq MU</searchLink>; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS. Electronic address: mmushtaq@kumc.edu. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101525386%22">Clinical lymphoma, myeloma & leukemia</searchLink> [Clin Lymphoma Myeloma Leuk] 2023 Mar; Vol. 23 (3), pp. 178-187. <i>Date of Electronic Publication: </i>2023 Jan 12. – Name: TypePub Label: Publication Type Group: TypPub Data: Meta-Analysis; Systematic Review; Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101525386 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2152-2669 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221522669%22">21522669 </searchLink><i>NLM ISO Abbreviation: </i>Clin Lymphoma Myeloma Leuk <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36682989 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.clml.2023.01.002 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 178 Titles: – TitleFull: Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Shahzad M – PersonEntity: Name: NameFull: Hussain A – PersonEntity: Name: NameFull: Tariq E – PersonEntity: Name: NameFull: Anwar I – PersonEntity: Name: NameFull: Faisal MS – PersonEntity: Name: NameFull: Syed L – PersonEntity: Name: NameFull: Karam A – PersonEntity: Name: NameFull: Chaudhary SG – PersonEntity: Name: NameFull: Ahmed N – PersonEntity: Name: NameFull: Bansal R – PersonEntity: Name: NameFull: Khurana S – PersonEntity: Name: NameFull: Singh AK – PersonEntity: Name: NameFull: Byrd KP – PersonEntity: Name: NameFull: Hematti P – PersonEntity: Name: NameFull: Abhyankar SH – PersonEntity: Name: NameFull: McGuirk JP – PersonEntity: Name: NameFull: Mushtaq MU IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 03 Text: 2023 Mar Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 2152-2669 Numbering: – Type: volume Value: 23 – Type: issue Value: 3 Titles: – TitleFull: Clinical lymphoma, myeloma & leukemia Type: main |
| ResultId | 1 |
